Julia Brown,
is a member of the Board of Directors of Labopharm, Inc. MediQuest Therapeutics, Inc. and Trius Therapeutics, Inc. She was a member of the Board of Directors of Tanox, Inc. from 2005 until its acquisition by Genentech in 2007. She serves on the business advisory board of CovX Pharmaceuticals. Julia is a member of the board of CONNECT and has just completed her second term as a trustee of the University of California, San Diego Foundation. She is a Tech Coast Angel, a member of BIOCOM, Corporate Director’s Forum, and Athena.
From 2000-2003, Julia was Executive Vice President of Amylin Pharmaceuticals, Inc. and continues to serve as Advisor to the CEO. Prior to joining Amylin, Julia was Executive Vice President of Dura Pharmaceuticals, Inc. She was with Dura from 1995-1999. Julia spent over 25 years with Eli Lilly and Company in progressively more senior roles. From 1992-1994, Julia was Vice President of IVAC Corporation and General Manager of its Vital Signs Division (a Lilly subsidiary). She was Vice President of Worldwide Marketing for Hybritech (another Lilly subsidiary), and led global marketing from1986-1992. She held a variety of positions in the pharmaceutical division, including eight years in the Company's international division. She did basic research in antimicrobials from 1969-1973. Julia is a graduate of Louisiana Tech University where she studied microbiology and biochemistry.